Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product

Joseph V Pergolizzi, Jr¹
Robert Taylor Jr¹
Jo Ann LeQuang¹
Robert B Raffa²,3

On behalf of the NEMA Research Group

¹NEMA Research Inc., Naples, FL, USA; ²University of Arizona College of Pharmacy, Tucson, AZ, USA; ³Temple University School of Pharmacy, Philadelphia, PA, USA

Abstract: Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be attained: the humanitarian/medical goal to relieve suffering and the societal/legal goal to not contribute to the drug abuse problem. This is an age-old problem, and the prevailing emphasis placed on one or the other goal has resulted in pendulum swings that have resulted in either undertreatment of pain or the current epidemic of misuse and abuse. In an effort to provide efficacious strong pain relievers (opioids) that are more difficult to abuse by the most dangerous routes of administration, pharmaceutical companies are developing products in which the opioid is manufactured in a formulation that is designed to be tamper resistant. Such a product is known as an abuse-deterrent formulation (ADF). ADF opioid products are designed to deter or resist abuse by making it difficult to tamper with the product and extracting the opioid for inhalation or injection. To date, less than a dozen opioid formulations have been approved by the US Food and Drug Administration to carry specific ADF labeling, but this number will likely increase in the coming years. Most of these products are extended-release formulations.

Keywords: oxycodone/naltrexone, abuse-deterrent formulation, abuse-deterrent opioid, oxycodone, abuse liability

Introduction

Opioids are indicated for the treatment of many forms of acute and chronic severe pain, but the abuse potential of opioids can make it challenging to offer them to patients at elevated risk for opioid misuse and abuse. Increasingly, clinicians face having to treat severe pain in patients at risk for opioid abuse or even with active substance abuse disorders. The emerging new category of abuse-deterrent formulations (ADFs) of opioid analgesics plays a major role in intending to provide analgesic benefit to patients, while deterring the potential that the oral analgesics can be crushed or dissolved (and thus cannot be smoked, inhaled, or drawn up into a syringe). The US Food and Drug Administration (FDA) has endorsed the development of ADF opioids.¹

ALO-02 (Troxyc® ER; Pfizer, New York, NY, USA) is a novel ADF analgesic product that combines a fixed dose of extended-release (ER) oxycodone (60 or 80 mg) plus the opioid antagonist naltrexone (7.2 or 9.6 mg, respectively) in a single oral pill designed to resist tampering efforts. It relies on similar technology used in another commercial product with ER morphine. ALO-02 contains tiny pellets of ER oxycodone surrounding a core of sequestered naltrexone 12% (Figure 1). If the product

Correspondence: Robert B Raffa
3825 E Diablo Canyon Place, Tucson, AZ 85718, USA
Email robert.raffa@temple.edu
is tampered with in an effort to obtain oxycodone, naltrexone may be released, which will block the opioid receptors (through which oxycodone produces its effects) and dampen the potential psychoactive effects of oxycodone. ALO-02 is intended for administration twice daily (every 12 hours) as an oral agent. It joins nearly a dozen other ADF products in the analgesic armamentarium. As opioids increasingly come under scrutiny for their abuse potential, it is of concern as to whether this new product adds versatility to clinical management of severe pain or it is joining an already overcrowded field. It is our aim in this narrative review to consider the evidence for and against this product and its potential role in the treatment of severe pain.

Materials and methods
On May 29, 2017, the PubMed, Embase, and Cochrane databases were searched using the term “oxycodone + naltrexone + pain” anywhere in the article and 35 results (PubMed), 0 (Embase), and 22 results (Cochrane Library) were obtained. No delimiters were used in the search which included all types of papers without restriction to publication date. In some instances, the bibliographies of these papers were also searched. Our goal was to create a narrative rather than a systematic review.

Abuse-deterrent products
ADFs of opioids are defined by the FDA as products which meet specific criteria aimed at resisting or deterring abuse. Four categories have been defined by the FDA based on the source of the evidence for abuse deterrence: drug formulations that resist in vitro manipulation and extraction; pharmacokinetic studies and in vivo properties of tampered dosages versus the intact product and a comparator; clinical abuse trials among recreational drug users; and postmarketing studies aimed at ascertaining the impact of an ADF product on abuse, misuse, and adverse outcomes. ADF labeling approved by the FDA is based on the information supplied by the sponsor regarding ADF tests that a particular product is able to pass. A variety of ADF technologies have come to market in the past decades, including those that make use of a physical barrier (making the product crush resistant or incapable of being dissolved), a chemical barrier, an aversive agent (such as capsaicin or niacin), and an opioid antagonist. ALO-02 relies on the strategy of combining an opioid agonist with an antagonist. Other ADF products using the opioid agonist/antagonist design are listed in Table 1.

The design of the agonist/antagonist combination may be accomplished in one of two ways: the antagonist may be released (“available”), but does not affect the agonist when the drug is taken properly, or the antagonist may be sequestered. “Available” antagonists are absorbed by the body when the drug is taken as prescribed. For example, a small amount of naloxone would be metabolized extensively in the first pass when the drug is taken orally with bioavailability of <2%; it would have virtually no effect on the agonist. On the other hand, a “sequestered” antagonist is not intended to be metabolized during appropriate oral ingestion, but would pass through the body. If the drug is manipulated, the sequestered antagonist would be released. The bioavailability of naltrexone is much greater than that of naloxone and, as a result, agonist/antagonist combination products using naltrexone must rely on sequestration.

A short history of agonist/antagonist ADF opioid analgesics
In 1969, Talwin® 50, a conventional oral formulation of 50 mg pentazocine hydrochloride, was approved in the USA for pain control. The drug became a target for abusers who found they could crush the pills easily (for inhalation) or dissolve them (for injection). This led to an abuse craze known as T’s & B’s (also Tops & Bottoms, T-shirts and Blue Jeans, and other slang terms) in which pentazocine (the T is taken from Talwin, the brand name) was combined with the first-generation antihistamine tripelennamine (trade name Pyribenzamine®), a blue tablet. Although T’s & B’s could be taken orally, the preferred route of administration...
among the most ardent abusers was intravenous (IV) injection. T’s & B’s were easy to abuse by injection in that no heating of the formulation was required. The formulation could be crushed, mixed with tap water, and then shaken before being drawn through cotton into a syringe in a process nicknamed a “cold shake”. So popular were T’s & B’s that one hard-hit Chicago rehabilitation clinic reported that around 1979, about 10% of its treatment clinic work was devoted to the abuse of this particular drug combination. To help deter abuse, Talwin’s manufacturer, Winthrop Laboratories, worked with the FDA and introduced a next-generation version of the product marketed as Talwin Nx, an oral fixed-dose combination product of 50 mg pentazocine plus 0.5 mg naloxone. When taken orally, the small amount of naloxone produced virtually no effect owing to its low bioavailability, but when the drug was dissolved and injected IV or intramuscularly, naloxone was released in sufficient amounts to counter the psychoactive effects of opioids. When Talwin Nx was introduced to market, the previous-generation Talwin 50 product was discontinued. In the 2 years following the introduction of Talwin Nx to market, emergency room mentions and medical examiner mentions for Talwin decreased by 70% and 71%, respectively, although the prescription rates for Talwin Nx increased slightly versus Talwin 50 in that same time frame.

At the time Talwin Nx was approved in 1982, the concept of ADF as a product category was unknown and the product carried no special ADF labeling. Talwin Nx was the manufacturer’s response to a public health problem. Unfortunately, it was still possible to abuse Talwin Nx by taking it orally.

Suboxone® (Reckitt Benckiser, Slough, Berkshire, UK) came to market in 2002 as a sublingual tablet of immediate-release (IR) buprenorphine combined with naloxone and indicated for the treatment of opioid dependence. In 2010, Suboxone sublingual film was introduced to make dosing easier and more convenient. This was an important agonist/antagonist combination product, but it had no labeled indication for pain treatment.

In 2010, King Pharmaceuticals developed Embeda®, a morphine ER capsule with sequestered naltrexone based on a proprietary coating technology. The use of naltrexone required that the antagonist be sequestered. When taken intact as an oral pill, the naltrexone passes through the body without effect; when the drug is manipulated, the naltrexone is released.

OxyContin®, a proprietary ER formulation of oxycodone, was cleared for market release in the USA in 1995. It became a frequently abused drug and was reformulated in 2010 in a crush-resistant ADF formulation as OxyContin

### Table 1 ADF and related products in which an opioid agonist and an antagonist are combined

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Antagonist</th>
<th>Technology</th>
<th>Brand name, manufacturer</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine</td>
<td>Naloxone</td>
<td>IR tablet and film with sequestered antagonist (film uses casing)</td>
<td>Suboxone®, Reckitt Banckiser Pharmaceuticals, Inc.</td>
<td>Not approved for use in pain syndromes</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Naloxone</td>
<td>IR film with BEMA technology</td>
<td>Bunavail® buccal film, BioDelivery Sciences International, Inc.</td>
<td>Approved in 2014</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Naloxone</td>
<td>IR tablet with lower dose than Suboxone</td>
<td>Zubsole®, Orexo AB</td>
<td>Approved in 2013</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>Naltrexone</td>
<td>Coated ER beads of morphine layered onto a sequestered core of antagonist</td>
<td>Embeda® ER capsule, King Pharmaceuticals since acquired by Pfizer, Inc.</td>
<td>Approved in 2009</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Naloxone</td>
<td>Crush-resistant technology</td>
<td>Targiniq® ER tablet, Purdue Pharma</td>
<td>Approved in 2014</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Naltrexone</td>
<td>ER oral capsules with film-coated beads, each of which has a core of sequestered naltrexone (0.0001 or 0.001 mg)</td>
<td>Troxyca® ER (ALO-02), Pfizer, Inc.</td>
<td>Approved in 2016; uses same ADF technology as Embeda ER</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Naltrexone</td>
<td>Ultra-low dose of naltrexone (0.0001 or 0.001 mg)</td>
<td>Oxytrex, Pain Therapeutics, Inc.</td>
<td>This is not an ADF product; the addition of naltrexone is intended to enhance analgesic effect; investigational drug</td>
</tr>
<tr>
<td>Pentazocine hydrochloride</td>
<td>Naloxone</td>
<td>IR tablet with naloxone</td>
<td>Talwin®, Sanofi Aventis</td>
<td>Approved in 1982, not technically an ADF product, but the manufacturer used a reformulation to make it more difficult to abuse drug</td>
</tr>
</tbody>
</table>

Note: Data from Maincent and Zhang.2

Abbreviations: ADF, abuse-deterrent formulation; BEMA, BioErodible MucoAdhesive; ER, extended release; IR, immediate release.
OP (sometimes called the “new oxy”). The abuse-deterrent version of OxyContin could still be abused by taking it intact orally, but oxycodone was frequently and by some abusers preferentially abused via non-oral routes. In a study of opioid rehabilitation patients who abused oxycodone, 88% said they primarily abused oxycodone by non-oral routes of administration, such as inhalation (snorting) or injection. The introduction of OxyContin OP disrupted these abuse patterns. First, ADF oxycodone decreased overall abuse for oxycodone as evaluated in abuse statistics from the past 30 days at rehabilitation treatment centers. Second, it shifted abuse of oxycodone to oral ingestion (76.1%) compared to snorting (25.4%) or injection (15.9%). Abuse and diversion of OxyContin decreased quarter-over-quarter for the first 5 years after the reformulation. One year after reformulation, the street price of OxyContin had dropped 36% versus the year before. Oxycodone was the subject of several reformulations in an effort to resist abuse (Table 2).

While the FDA has advocated for ADF opioid analgesics, these new ADF opioids have raised certain important concerns. First, will the wider availability of so-called ADF products cause prescribers to be less cautious about opioid prescribing, that is, will they engender a false sense of security that abuse is less likely? Another important question involves cost: will the use of ADFs result in greater costs to the already overtaxed health care system, since these products are generally more expensive than conventional, generic opioids? In a survey based on data from the IMS Health National Prescription Audit database, opioid prescriptions from 1992 to 2016 were analyzed. From 1992 to 2010, opioid analgesics were prescribed in steadily increasing numbers, but things changed in 2010 (the year reformulated OxyContin was introduced). From 2010 to 2015, the number of dosing units per ER opioid prescription dropped 20% (from 67 to 54) and the total weight of opioids prescribed in the USA decreased 16%. The total number of dispensed opioid prescriptions decreased versus the previous year by 2.2% and 6.8% in 2014 and 2015, respectively. Thus, there are strong trends driving down opioid prescribing, among which the role of ADF products likely plays a part.

**ADF opioids are not perfect**

It is still possible to take ADF products intact orally and in some cases, the product can still be manipulated by skillful or dedicated abusers, many of whom publish their “hacks” online. Furthermore, it should be noted that the most commonly reported route of abuse for opioids is oral (64.0%). However, death or major adverse effects are twice as likely to occur when prescription opioids are abused via non-oral routes of administration than when they are taken orally, such that ADF products have the potential to make a significant impact on public health.

It is not realistic to consider that ADF opioids are abuse-proof, but rather that they – like locks on cars – simply make certain forms of illegal acts more difficult, time consuming, cumbersome, and inconvenient. At best, ADF products help to deter abuse among those who are deliberately trying to tamper with the oral products in order to inhale, smoke, or inject the opioid. ADF products must be viewed with a balanced appraisal – they are at most one piece in the mosaic of things that can be done to minimize opioid misuse and abuse.

**Defining severe pain**

Opioids are frequently indicated in cases of severe pain of various etiologies including acute pain, traumatic pain, cancer pain, noncancer pain, and postsurgical pain. The World Health Organization in its seminal document on cancer pain treatment described pain in terms of intensity, identifying three levels (mild, moderate, severe). While pain is a multidimensional experience, pain intensity

### Table 2 Oxycodone is available in several ADF products

<table>
<thead>
<tr>
<th>Brand name, manufacturer</th>
<th>Technology</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytrex, Pain Therapeutics, Inc.</td>
<td>Product uses an ultra-low dose of naltrexone (0.0001 or 0.001 mg) intended to enhance analgesia</td>
<td>Not technically an ADF product; investigational drug</td>
</tr>
<tr>
<td>Roxybond®, Inspirion Delivery Sciences</td>
<td>SentryBond® technology formulated with inactive ingredients to make it difficult to crush or dissolve the pill</td>
<td>Only immediate-release opioid in ADF, approved in 2017</td>
</tr>
<tr>
<td>Targiniq® ER, Purdue Pharma</td>
<td>Agonist/antagonist, crush-resistant technology</td>
<td>Approved in 2014</td>
</tr>
<tr>
<td>Troxyca® ER (ALO-02), Pfizer, Inc.</td>
<td>Agonist/antagonist, ER oral capsules with film-coated beads. Each bead has a core of sequestered naltrexone</td>
<td>Approved in 2016</td>
</tr>
<tr>
<td>Xtampza® ER, Collegium Pharmaceuticals</td>
<td>Microspheres in the formulation make it difficult to extract the opioids by crushing, grinding, or dissolving</td>
<td>Approved in 2016</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADF, abuse-deterrent formulation; ER, extended release.
in and of itself remains a valuable and readily understood clinical metric. Pain is inherently subjective, but the tools to measure pain, such as the visual analog scale and variations or numeric rating scale, have been validated for use in clinical practice. Many tools generally consider pain ≥7 on an 11-point scale to be “severe,” but other studies suggest that the cutoff value between moderate and severe pain is 8 rather than 7. Pain can also limit function, but pain severity is not linearly related to functional deficits. In fact, on an 11-point scale, the transitions from 4 to 5 and from 6 to 7 are the most influential differences in terms of functional limitations. Functional aspects of pain can be useful and relevant metrics, but do not necessarily correlate well with pain intensity. For example, a bedridden patient at the end of life may be in severe pain, but adequate analgesia may offer him/her no functional advantages. However, it can still be clinically relevant for many patients to discuss pain intensity in terms of function. In general, mild pain is such that many patients can go about their everyday activities with minimal disruption; mild pain may be troublesome, but is not necessarily a significant distraction to ordinary everyday life. Moderate pain, on the other hand, is more difficult to ignore. The patient may seek out medical care or pain treatment and it may limit the patient’s activities to some degree. Moderate pain is much harder for the patient to ignore, although it may not yet reduce functionality in a substantial way. Finally, severe pain is impossible to ignore, likely decreases function, can disrupt sleep, and may adversely affect mood.

While both cancer and noncancer pain rely on the designations mild, moderate, and severe to describe pain intensity, the experience of pain may be fundamentally different – and more severe – for cancer versus noncancer pain patients. For example, noncancer pain tends to be more stable than cancer pain, which may be associated with unpredictable episodes of breakthrough pain. Cancer pain can vary markedly from day to day or even hour to hour, and can worsen with disease progression and specific treatments. Since worsening cancer pain may be indicative of progressing disease, invading tumors, or a poor prognosis, exacerbated cancer pain carries with it emotional impact as well as physical pain. Certain forms of cancer pain, such as bone metastases, may interfere with function as well as cause pain, which may amplify the negative experience of pain. Thus, pain etiology may impact how patients perceive pain and how pain impacts them, although this has not been formally elucidated. For example, cancer patients report a significantly higher level of physical interference than noncancer pain patients even at the same level of pain intensity.

It has been suggested that geriatric patients have lower pain thresholds than younger patients but the physiologic reasons for these differences remain unclear. Intriguingly, recent studies have found obese individuals tend to have higher pain thresholds than nonobese individuals, although the reasons for this remain to be explored. Ethnic and culture differences may also impact how a patient perceives and responds to pain. Racial differentials in pain perception as well as pain experience have also been documented but there is also evidence that there are racial disparities in terms of access to adequate analgesia. Thus, racial differences in pain perception may be caused by inadequate analgesia rather than truly different perceptions of pain. Gender may play a role as well; women tend to report more pain than men, but it has been suggested this has to do with gender roles rather than biology.

Thus, clinicians treating patients in pain should be cognizant of the fact that the pain intensity is part of a much larger picture. Moreover, some patients may underreport their pain levels such that certain “moderate” pain syndromes may, in fact, reflect pain of severe intensity. There may be subtle gradations in the painful experiences of their patients based on the patient’s pain etiology, diagnosis, prognosis, cultural background, and other factors. For these reasons, it is helpful to take a holistic approach to pain control and individualize analgesic regimens to meet the specific needs of the patient.

**Clinical studies**

ALO-02 has been evaluated in a variety of clinical studies for its abuse liability and its pain-relieving benefits in specific pain syndromes.

**Abuse potential**

In a double-blind, placebo- and active-controlled, six-way crossover study, 75 nondependent, recreational opioid users were randomized to take intact ALO-02 40 mg, crushed ALO-02 40 and 60 mg, crushed IR oxycodone 40 and 60 mg (active control), or placebo. Compared to placebo, drug liking and reported time to maximum effect (E_max) were significantly greater for oxycodone IR (p<0.0001) than placebo; compared to oxycodone IR, both doses of crushed and intact ALO-02 were significantly lower in terms of likeability and E_max (p<0.0001 for both doses). Adverse events (AEs) were fewer in the ALO-02 groups compared to the oxycodone groups (from 71.1% to 91.9% versus 100%, respectively). This study suggests that the oxycodone/naltrexone product has a lower abuse potential than oxycodone IR and is well tolerated.
A placebo- and active-controlled, double-blind, four-way, crossover study examined the abuse potential of crushed ALO-02 inhaled nasally (“snorted”) in healthy, nondependent, recreational opioid users. A total of 32 subjects were randomized to four groups: a crushed single dose of one of two placebos, a crushed dose of ALO-02 30/3.6 mg (oxycodone/naltrexone), or a crushed dose of oxycodone IR 30 mg. Crushed ALO-02 scored significantly lower than crushed oxycodone IR for drug liking and \( E_{\text{max}} \) (60.5 versus 92.8, respectively, and 24.2 versus 86.9, respectively; \( p<0.0001 \)). This suggests lower abuse potential for ALO-02 compared to oxycodone IR.

A double-blind, placebo-controlled, three-way crossover study randomized 33 recreational nondependent opioid users to receive IV oxycodone 20 mg, IV crushed ALO-02 20/2.4 mg (oxycodone/naltrexone), or IV placebo. Drug liking was significantly greater for oxycodone than ALO-02 or placebo \( (p<0.0001 \text{ for both}) \); likewise, the quality of the psychoactive effect was significantly greater for oxycodone than placebo (but not significantly greater than ALO-02).

“Dose dumping” occurs when a large amount of opioid is rapidly released from a controlled-release product, and it is one way that abusers seek to manipulate ER opioid products. Abusers may provoke dose dumping by taking the drug together with alcohol, in that some ER formulations are more soluble in alcohol than water. Furthermore, alcohol may also increase the permeability of drugs in the gastrointestinal tract. An open-label, single-dose, three-way crossover study randomized 18 healthy fasting subjects to be administered ALO-02 20/2.4 mg (oxycodone/naltrexone) under naltrexone block with one of three liquids: water, 20% ethanol, or 40% ethanol. Mean time to maximum concentration \( (C_{\text{max}}) \) was 12 hours postdose for ALO-02 administered with water, but dropped to 8 hours when ALO-02 was taken with 40% ethanol. The area under the plasma concentration time curve value from time zero extrapolated to infinity was similar for ALO-02 administered with water compared to 20% ethanol, but increased about 37% when ALO-02 was taken with 40% ethanol. The rate of AEs increased with ALO-02 plus ethanol versus ALO-02 with water. Thus, \( C_{\text{max}} \) (which helps to define oxycodone exposure) increases with 40% ethanol but not with 20% ethanol, compared to ALO-02 taken with water.

Chronic low back pain is a prevalent disorder and may be associated with severe pain. A double-blind, placebo-controlled study of patients with moderate to severe chronic low back pain was designed with an open-label phase of at least 4 weeks, during which all patients received ALO-02 at doses ranging from 20 to 160 mg/day. In the open-label phase of the study, the median daily dose of ALO-02 was 20 mg (mean 23.3 mg, range 10–160 mg), which increased to 60 mg (mean 62.9 mg, range 10–160 mg) at the end of the open-label phase of about 4 weeks. The open-label phase was followed by a patient screening, and those who met the criteria (pain scores \( \leq 4 \), tolerated ALO-02, fixed dose established) could enter a double-blind study and were randomized to receive ALO-02 or placebo for 12 weeks with up to 3 g/day acetaminophen as rescue medication. A total of 663 patients were included in the study: 410 completed the open-label phase and 281 entered the double-blind phase. About a third of patients (31.5%) discontinued participation in the study at the end of the open-label phase, most frequently because of AEs. Pain scores were significantly improved in ALO-02 patients from baseline to the 10th week of the study, with 44% of placebo and 57.5% of ALO-02 patients reporting \( \geq 30\% \) improvement in pain scores. Upon entrance to the study, their overall pain scores were 7.0; the scores dropped to 3.1 at the conclusion of the open-label phase. In the open-label phase of the study, the median daily dose of ALO-02 was 20 mg (mean 23.3 mg, range 10–160 mg) and increased to 60 mg (mean 62.9 mg, range 10–160 mg) at the end of the open-label phase of about 4 weeks. During the double-blind phase, 43.3% of placebo and 34.9% of ALO-02 patients used rescue analgesia. Side effects were generally mild to moderate, with the most commonly reported AEs being nausea, constipation, and vomiting.

Chronic noncancer pain describes a variety of painful conditions, including but not limited to musculoskeletal pain. In an open-label, year-long safety study, 395 patients with various types of moderate to severe chronic noncancer pain received ALO-02 at doses ranging from 20 to 160 mg (oxycodone) per day. Included in this study were both opioid-experienced and opioid-naïve patients. Pain severity scores on the Brief Pain Inventory Short Form decreased over time, and the most common treatment-emergent AEs were nausea (25.3%), constipation (21.3%), vomiting (13.9%), and headache (11.6%). The most frequently reported drug-related AEs were constipation (18.0%), nausea (14.9%), somnolence (8.4%), fatigue (6.8%), dizziness (5.6%), and vomiting (5.1%).

Clinical issues

When arriving at a prescribing choice for the control of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, a series of important clinical decisions are
required. These questions are evaluated in the following section with the focus on ADF oxycodone/naltrexone as an option.

When to consider opioid analgesia
As a general rule, opioids are not usually the first-line agents to manage pain unless the pain is acute (e.g., traumatic pain or postsurgical pain) or overwhelmingly severe. Guidelines for various pain syndromes usually specify that nonopioid analgesics, such as acetaminophen, and nonsteroidal anti-inflammatory drugs be utilized first and opioids trialed only if nonopioid therapy does not offer adequate analgesia.51–50 Thus, patients with pain associated with osteoarthritis may first be administered acetaminophen or nonsteroidal anti-inflammatory drugs and progress to opioids only if these agents do not provide adequate pain control.

Opioid therapy in an opioid-naïve patient should commence as a trial rather than the initiation of long-term therapy. The patient and caregivers should be informed about the potential risks as well as benefits of opioid therapy. In some cases, informed consent or another type of agreement should be signed to assure that the patient understands not just the risks of opioid therapy but the clinician’s expectation for patient compliance as well. Patients should be educated about possible side effects, so that they are reported promptly. Clinicians should consider opioid therapy only if the expected benefits for both pain and function are anticipated to outweigh the risks to the patient.51 Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if the benefits do not outweigh the risks.51 Clinicians should review the patient’s history of controlled substance prescriptions using state prescription drug monitoring program data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose.51 Clinicians should review prescription drug monitoring program data when starting opioid therapy for chronic pain.51

Opioids should be started at a low dose under close supervision; not all patients tolerate them well. Pain should be evaluated and discussed frequently, as not all patients find effective pain control with opioids. In some cases, pain control may improve with changes in dose or opioid rotation, but in other cases, patients may decide that opioids are not effective. It should be noted that opioids are not necessarily appropriate for all pain syndromes, including the severe pain associated with migraine and fibromyalgia.52

Before starting opioid therapy, universal precautions should be exercised,53 so that the patients at risk for potential opioid misuse and abuse can be identified. Clinicians should talk frankly with their patients about the nature of opioid therapy. A variety of validated screening tools exist to assess opioid abuse risk in individual patients.54–56 The most prominent risk factor for opioid abuse is a history of active substance abuse, but there are multiple risk factors. In fact, long-term opioid therapy itself may be a risk for abuse.57 For patients at risk of opioid abuse, ADF formulations can be an important option.

Opioids should be considered only when their potential analgesic benefits outweigh their associate side effects.58 Opioid-associated side effects are well documented in the literature and can be treatment limiting.59 Many AEs can be managed, which is important because side effects can increase discomfort in patients already at great distress due to pain.

When to consider ADFs of opioids
ADF products may be appropriate for patients in severe pain even if these patients themselves are not at elevated risk for opioid abuse. Long-term opioids are typically dispensed as a 30-day supply, or even more, meaning that a number of pills will be stored in the household and could be purloined by other household members or guests. Recreational opioid users report that they can often get drugs by stealing them from friends and family members.60 Thus, ADF oxycodone may be an important product for outpatient use in busy or multi-person households where drugs may not be carefully secured between doses.

Only a subset of opioid analgesics is available in ADF formulations and none are generic. ADF products cost more than their generic counterparts, a factor that can play a major role in product selection. Indeed, many payers may not reimburse for ADF opioids. An argument may be made that since most patients prescribed opioids will not abuse them, they derive no benefit from ADF products and should therefore not have to pay the incremental costs for ADF technology. ADF products are still important in that they are designed to resist or deter abuse, whether it is carried out by the patient or a person who has access to that patient’s drugs. Furthermore, as ADF products increasingly crowd out conventional, non-ADF opioids in the marketplace, prescription opioids become more difficult to abuse overall.

Opioid rotation
Opioid rotation – switching from one opioid type and formulation to another – is a recognized analgesic strategy and can be used before abandoning opioid therapy when the patient has inadequate analgesia or intolerable side effects
on the current regimen. Strategies to convert the doses of the opioids have been published, but generally involve establishing an equianalgesic dose and then starting the patient on a somewhat lower than equianalgesic dose of the new opioid and titrating slowly and carefully to achieve pain relief with tolerable side effects.

In some cases, it may be helpful to rotate a patient from a conventional product to an ADF formulation. It should be noted that not all opioid products are available in an ADF formulation. There may be occasions when the patient must discontinue an ADF product and move to another opioid which is not available in ADF version. In this case, clinicians must consider whether the patient is genuinely experiencing a lack of efficacy and/or treatment-limiting side effects or the patient may simply want to manipulate the clinician into prescribing a different opioid that may be more vulnerable to tampering.

Of course, rotating a conventional non-ADF opioid product to an ADF formulation does not necessarily mean no abuse will occur. ADF products are still vulnerable to abuse by those who wish to ingest them intact orally, and, in some cases, ADF products can be “hacked” by those resourceful enough to figure out strategies to defeat the ADF mechanisms.

**Treating severe pain in opioid-experienced patients**

If patients with severe pain are opioid experienced, tolerance has likely developed with prolonged opioid exposure. Opioids should be titrated to the effective dosage, which may be high in opioid-experienced patients with severe pain. It is important to consider carefully complaints raised by patients about inadequate analgesia. In some cases, the patients may be experiencing tolerance, in which cases, judicious titration to a higher dose of opioids is appropriate. Tolerance to one opioid may also be addressed by rotating to a different opioid which may be effective at lower doses. In other cases, the patient may ask for higher doses because he or she is seeking to obtain more drugs. It is also important to consider the seemingly paradoxical condition of opioid-induced hyperalgesia in which prolonged exposure to opioids lowers the pain threshold. In the latter case, opioids should be tapered and discontinued in favor of a different analgesic regimen.

The Centers for Disease Control and Prevention have advocated against high doses of opioids. However, high doses of opioids for individual patients might be justified, particularly for palliative care cancer patients at the end of life or patients in severe or very severe pain of likely limited duration (e.g., traumatic injury, burn patients, severe postsurgical pain). The use of high-dose opioid therapy may increase the risk of opioid abuse. In addition, high-dose opioid therapy has been associated with other health-related concerns, more severe pain intensities, and greater utilization of health care resources.

**Treating pain in active substance abusers**

Prescribers increasingly face the conundrum of having to manage pain in past or active substance abusers. For example, heroin addicts are not rare and their propensity to suffer from painful infections and osteomyelitis along with overdose and other conditions means that they frequently are managed by the health care system. Yet, the literature contains very little with respect to how to manage pain in heroin addicts. There are several key considerations for this population. First, heroin abusers may not be forthcoming about their addiction, particularly if they fear that honesty might result in legal repercussions or that they might be denied medical care and/or pain control. Second, even if heroin abusers are transparent about their drug use, street heroin is frequently cut with fentanyl or other adulterants and purity varies widely – it is practically impossible for heroin addicts to accurately report what drug(s) and how much they are taking. Third, few clinicians feel confident in treating them. Finally, heroin addicts (like opioid-experienced patients) typically have developed tolerance, such that relatively high and/or frequent doses of opioids are needed to control their acute pain.

The notion that opioid addicts do not feel pain is a myth. Opioid addicts in acute pain may be administered opioid analgesics at a dose needed to manage both pain and withdrawal symptoms, but it is important to discuss the pain management plan in advance to manage patient and provider expectations.

Also encountered in clinical practice are patients on medication-assisted therapies to treat opioid abuse, such as methadone maintenance programs or buprenorphine maintenance. They also pose a challenge for clinical pain management. Such patients often have high tolerance to opioids, but their opioids – which may be dosed only every 24 or 48 hours – likely provide little analgesic benefit. In such cases, the medication-assisted therapy should be continued with short-acting opioids prescribed to provide acute pain control.

The idea that a substance abuser with a legitimate pain syndrome should be denied pain control cannot be supported. However, long-term pain control in substance abusers becomes problematic.

Many opioid addicts have or have had legitimate painful conditions. In a survey of 199 young subjects (mean age 24.6 years) in which 59.8% of participants reported non-medical use of a prescription opioid at least once a week,
the majority of subjects said that at one time or another, they had severe pain (86.2% of men and 84.1% of women). Of these patients, most said that they used prescription opioids nonmedically to treat their pain (72.3% of men and 81.2% of women) and that their physician(s) had refused to prescribe opioids to them to treat their severe pain (26.9% of men and 36.2% of women). In this survey, reporting higher intensities of physical pain could be statistically correlated to nonmedical use of opioids \( (p=0.002) \). This suggests that denying pain therapy to opioid abusers simply drives them to find illicit substances. In a retrospective database study (2006–2015) evaluating 5,307 adult patients diagnosed with an opioid use disorder, 61.8% had some sort of chronic painful condition as well as the patient’s opioid abuse. A patient–provider agreement should be worked out and put into writing describing the expectations of therapy. ADF products are appropriate for such patients, even if they claim that they would not inhale or inject an opioid. The exact strategies for managing pain in patients with substance abuse disorders goes beyond the scope of this article, but is an important and extremely timely clinical topic.

**Conclusion**

Oxycodone ER is an effective opioid reliever for severe pain, and its incorporation into an ADF product with sequestered naltrexone is designed to resist abuse by those who want to smoke, inhale, or inject the active agent. ALO-02 is a novel product that may be a versatile and useful addition to the armamentarium of pain relievers.

**Acknowledgment**

The authors wish to acknowledge and thank John Bisney for his expert editorial assistance and discussions.

**Disclosure**

JVP consults for multiple pharmaceutical companies involved in the discovery/development of analgesics, and is the co-founder of NEMA Research and Neumentum, a non-opioid analgesics company. RBR consults for several pharmaceutical companies involved in analgesics drug discovery/development, but receives no royalties for sales of any product, and is investor in Neumentum and co-founder of CaRafe, both non-opioid analgesics discovery/development companies. The authors report no other conflicts of interest in this work.

**References**


